Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF

NCT04464525 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.

NCT NCT04464525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04464525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Omecamtiv Mecarbil Post-trial Access Protocol for Subjects Completing Study 20110203 GALACTIC-HF
Lead sponsor
Cytokinetics
Phase
Phase 3
Overall status
Withdrawn
Start date
December 18, 2020
Completion date
November 27, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure with reduced ejection fraction